Literature DB >> 6749206

Effect of treatment on the evolution of renal abnormalities in lupus nephritis.

J E Balow, H A Austin, L R Muenz, K M Joyce, T T Antonovych, J H Klippel, A D Steinberg, P H Plotz, J L Decker.   

Abstract

We retrospectively studied the evolution of histopathologic features in successive renal biopsies in patients with lupus nephritis, to evaluate the effects of various treatment regimens. Repeat renal biopsies had been performed in 62 patients after more than 18 months of observation (median interval, 44 months) in randomized therapeutic trials comparing prednisone with cytotoxic drugs. Renal histopathologic features were graded individually, and a composite score reflecting the number and severity of irreversible lesions was defined as a chronicity index. The chronicity index for patients treated with conventional high-dose prednisone increased linearly with the interval between biopsies, whereas the index in the group receiving cytotoxic-drug treatments did not increase over time. After statistical adjustment for important prognostic factors (age and initial chronicity index) identified by multiple linear regression, the difference in the slopes between the group receiving prednisone and the group receiving cytotoxic drugs was significant (P less than 0.0001). We conclude that cytotoxic-drug treatment reduces the likelihood of progressive renal scarring in lupus nephritis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6749206     DOI: 10.1056/NEJM198408233110802

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  29 in total

Review 1.  Combination treatment in autoimmune diseases: systemic lupus erythematosus.

Authors:  G Moroni; O Della Casa Alberighi; C Ponticelli
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Stem cell transplantation: limits and hopes.

Authors:  K P Machold; J S Smolen
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

Review 3.  Kidney disease in systemic lupus erythematosus.

Authors:  J E Balow
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

4.  Glucocorticoid enhances hypoxia- and/or transforming growth factor-β-induced plasminogen activator inhibitor-1 production in human proximal renal tubular cells.

Authors:  Hideki Kimura; Xuan Li; Kunio Torii; Toshiharu Okada; Kazuko Kamiyama; Daisuke Mikami; Kenji Kasuno; Naoki Takahashi; Haruyoshi Yoshida
Journal:  Clin Exp Nephrol       Date:  2010-11-03       Impact factor: 2.801

Review 5.  Cyclophosphamide toxicity. Characterising and avoiding the problem.

Authors:  L H Fraiser; S Kanekal; J P Kehrer
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

6.  Lupus nephritis. Middlesex, October 20, 1988. Abstracts.

Authors: 
Journal:  Postgrad Med J       Date:  1989-05       Impact factor: 2.401

7.  Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide.

Authors:  I Martin-Suarez; D D'Cruz; M Mansoor; A P Fernandes; M A Khamashta; G R Hughes
Journal:  Ann Rheum Dis       Date:  1997-08       Impact factor: 19.103

8.  Lupus nephritis: more answers needed.

Authors:  F Wang
Journal:  J R Soc Med       Date:  1985-08       Impact factor: 5.344

9.  New approaches to treating systemic lupus erythematosus.

Authors:  D Wofsy
Journal:  West J Med       Date:  1987-08

Review 10.  The treatment of lupus nephritis.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.